IO Biotech

IO Biotech Equity

Delisted·Sep 22, 2026

The The Equity of IO Biotech (IOBT) as of Nov 20, 2026 is 47.02 M USD. In the previous year, The Equity was 133.16 M USD — a change of -64.69% (lower).

Equity

47.02 MUSD

YoY

-64.69%

Last updated:

In 2024, IO Biotech's equity was 47.02 M USD, a -64.69% increase from the 133.16 M USD equity in the previous year.

The IO Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-1.47 M USD
Jan 1, 2020
2.60 M USD
Jan 1, 2021
211.92 M USD
Jan 1, 2022
138.85 M USD
Jan 1, 2023
133.16 M USD
Jan 1, 2024
47.02 M USD
The IO Biotech Equity history
YEAREquityYoY
47.02 MUSD-64.69%
133.16 MUSD-4.10%
138.85 MUSD-34.48%
211.92 MUSD+8,041.53%
2.60 MUSD-276.95%
-1.47 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing IO Biotech's Equity

IO Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding IO Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating IO Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

IO Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in IO Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about IO Biotech stock

The Equity of IO Biotech is 47.02 M USD in 2024.

The Equity of IO Biotech changed from 133.16 M USD to 47.02 M USD, representing a -64.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity IO Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's IO Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IO Biotech

All Key Metrics — IO Biotech